A Walker 256 tumor-induced osteogenic small animal model for the evaluation of [99mTc] diphosphonate radiopharmaceuticals.
A mammalian model has been developed for the in vivo evaluation of bone imaging agents. The model is based upon the quantification of a discrete, initial secondary periosteal osteogenesis induced in cortical bone immediately adjacent to an intramuscularly implanted Walker 256 tumor in Fisher 344 rats. Evaluation of the model consists of a histopathological examination of the periosteal bone formation, biodistribution studies on 99mTc-MDP and 99mTc-HMDP commercial kit preparations, and biodistribution studies on two 99mTc-HEDP component fractions isolated after anion exchange chromatographic separations from an investigative "carrier added" preparation. Reversed phase HPLC separations of the 99mTc-MDP and 99mTc-HMDP commercial kit preparations illustrate distinct differences in chemical composition between the two bone agents.
D000818:Animals; D001859:Bone Neoplasms / Q000000981:diagnostic imaging*; D002279:Carcinoma 256, Walker / Q000000981:diagnostic imaging*; D004164:Diphosphonates; D008297:Male; D051379:Mice; D011877:Radionuclide Imaging; D051381:Rats; D011916:Rats, Inbred F344; D011933:Reagent Kits, Diagnostic; D013667:Technetium; D017556:Technetium Compounds; D014018:Tissue Distribution
D004164:Diphosphonates; D011933:Reagent Kits, Diagnostic; D017556:Technetium Compounds; D013667:Technetium; C029045:technetium Tc 99m diphosphonate